Telo Genomics Announces $250,000 Term Loan Facility
The financing requires tax-credit payments to go directly to the lender and SR&ED claims to be filed within a specified deadline.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Telo Genomics (OTCQB: TDSGF) closed a $250,000 term loan agreement with BrightArc Capital Adminco 1, effective October 29, 2026.
The non-dilutive, demand, non-revolving facility has provided an initial $100,000 advance, with the balance to follow later. Interest is 1.30% monthly, equivalent to 15.60% annually, payable monthly in arrears. Repayment within three months requires at least three months of interest. A three-month interest reserve is required and may be deducted from the advance.
The loan is secured by present and after-acquired personal property and an irrevocable assignment of Scientific Research and Experimental Development (SR&ED) tax credits and refunds. The outstanding balance is due at the earlier of three business days after receipt of SR&ED claims for the tax year ended in 2026 or twelve months from advance. Proceeds will fund general operating expenses.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point$250,000 non-dilutive facility provides operating funding; an initial $100,000 advance has been received. 6.9% of market cap
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Demand, non-revolving loan adds secured debt, with the remaining advance to follow at a later date.
- Minor point1.30% monthly simple interest, equivalent to 15.60% annually, is payable monthly in arrears.
- Minor point. Forward-looking: it has not happened yet and may not happen.Three months of interest is the minimum payable if repaid within three months of advance.
- Minor point. Forward-looking: it has not happened yet and may not happen.Three-month interest reserve is required and may be deducted from the advance.
- Minor pointPresent and after-acquired personal property secures the loan; SR&ED tax credits and refunds are irrevocably assigned.
3 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Repayment deadline is the earlier of three business days after 2026 SR&ED claims receipt or twelve months from advance.
- Minor point. Forward-looking: it has not happened yet and may not happen.SR&ED claims must be filed within 180 days of the June 30 financial year end.
- Minor point. Forward-looking: it has not happened yet and may not happen.CRA payments must be directed to the lender's account through maintained direct deposit instructions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Non-dilutive secured term loan from BrightArc Capital to fund operating expenses.
Vancouver, British Columbia--(Newsfile Corp. - November 6, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on three-dimensional analysis of telomeres (which are the ends of chromosomes), today announced that it closed a term loan agreement effective October 29, 2026, with BrightArc Capital Adminco 1 Inc. (the "Lender") for a principal amount of
The Term Loan is a demand non-revolving facility. The Company has received an initial advance of
The outstanding balance (principal, accrued interest and other amounts) is due on the earlier of (i) three business days after the Company receives its SR&ED claims for the tax year ended in 2026 or (ii) twelve months from the date of advance. An interest reserve equal to three months of interest is required and may be deducted from the advance. The Term Loan agreement also includes covenants requiring timely filing of SR&ED claims (within 180 days of the Company's June 30 financial year end) and maintenance of direct deposit instructions so that CRA payments are directed to the Lender's account, as well as various negative covenants typical of this type of facility.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 190+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM, is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
John Price, Chief Financial Officer
John.Price@telodx.com
Tel: 408-550-5767
555 Richmond Street West
Toronto, ON, Canada, M5V 3B1
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information in this news release may constitute "forward-looking information" under Canadian securities legislation. Forward-looking information is often identified by words such as "intends," "believes," "may," "could," "objective," "estimate," or statements that certain events "will" occur. Forward-looking statements in this release include, without limitation, statements regarding the use of proceeds of the Term Loan, the advance of the balance of the Term Loan, the expected timing of SR&ED claims, and the Company's ability to meet the terms and covenants of the facility. Forward-looking statements are based on assumptions that the Company considers reasonable as of the date of this release, including that the Term Loan will be advanced as contemplated, that SR&ED claims will be filed and received on a timely basis, and that the Company will maintain compliance with the facility covenants. Those assumptions may prove incorrect. Actual results may differ materially because of known and unknown risks and uncertainties, including the risk that SR&ED claims will be delayed, reduced or denied, that the Company will not generate sufficient cash flow to service or repay the Term Loan, that the balance of the Term Loan will not be advanced, that additional financing may be required on unfavorable terms, and other risks described in the Company's filings on SEDAR+. Readers should not place undue reliance on forward-looking statements. The Company does not undertake to update forward-looking statements except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/322920
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much financing has Telo Genomics secured from BrightArc Capital?
Telo Genomics closed a $250,000 non-dilutive term loan facility with BrightArc Capital Adminco 1, effective October 29, 2026. An initial $100,000 advance has been received, with the balance to be advanced later. The proceeds will fund general operating expenses.
What interest rate and repayment terms apply to Telo Genomics' term loan?
The loan carries 1.30% monthly simple interest, equivalent to 15.60% annually, and is a demand facility. The outstanding balance is due at the earlier of three business days after receipt of SR&ED claims for the tax year ended in 2026 or twelve months from advance. Interest is payable monthly in arrears.
What tax-credit filing and payment requirements does Telo Genomics' loan impose?
Telo Genomics must file its SR&ED claims within 180 days of its June 30 financial year end and maintain direct deposit instructions directing CRA payments to the lender's account. SR&ED refers to Scientific Research and Experimental Development.